Faruqi & Faruqi investigates Unicycive Therapeutics securities class action.

Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. for alleged securities violations between March 29, 2024 and June 27, 2025. Investors who suffered losses are encouraged to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) or click here for additional information. The deadline to seek the role of lead plaintiff is October 14, 2025.

Unicycive Therapeutics, Inc. (UNCY), a biotechnology company listed on NASDAQ, is facing a class action lawsuit alleging securities law violations. The lawsuit, filed by investors, claims that the company made false and misleading statements regarding its manufacturing compliance with the FDA and the regulatory prospects of its new drug application. Investors are encouraged to contact legal firms to discuss their rights and potential recovery.

The lawsuit, filed by Bronstein, Gewirtz & Grossman, LLC, alleges that Unicycive Therapeutics, Inc. made materially false and misleading statements and failed to disclose critical information between March 29, 2024, and June 27, 2025. The firm asserts that these statements overstated Unicycive's readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application. As a result, investors who purchased UNCY shares during this period may have suffered losses [2].

Faruqi & Faruqi, LLP has also begun investigating potential claims against Unicycive Therapeutics, Inc. Investors who suffered losses are urged to contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their rights. The deadline to seek the role of lead plaintiff is October 14, 2025 [3].

Investors have until October 14, 2025, to request that the Court appoint them as lead plaintiffs in the case. Participation in the class action does not require serving as a lead plaintiff. There is no cost or obligation to participate, and if successful, investors may be entitled to compensation without paying any out-of-pocket costs or fees [1].

Levi & Korsinsky, LLP, a prominent securities litigation firm, has also notified investors about the lawsuit and encourages those who suffered losses to contact Joseph E. Levi, Esq., at jlevi@levikorsinsky.com or by telephone at (212) 363-7500 [1].

The Gross Law Firm, another law firm involved in the case, emphasizes the importance of acting promptly and provides a deadline of October 14, 2025, for shareholders to register their claims. The firm also offers portfolio monitoring software to keep investors updated on the case's progress [3].

Investors are advised to carefully review the details of the lawsuit and consult with legal professionals to understand their rights and potential remedies. The class action lawsuits against Unicycive Therapeutics, Inc., highlight the importance of transparency and accuracy in corporate disclosures to protect investors.

References:
[1] https://www.morningstar.com/news/pr-newswire/20250822ny56832/unicycive-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-before-october-14-2025-to-discuss-your-rights-uncy
[2] https://www.globenewswire.com/news-release/2025/08/18/3135284/9788/en/UNCY-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Unicycive-Therapeutics-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html
[3] https://www.globenewswire.com/news-release/2025/08/21/3137504/0/en/Class-Action-Filed-Against-Unicycive-Therapeutics-Inc-UNCY-October-14-2025-Deadline-to-Join-Contact-The-Gross-Law-Firm.html